Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ ...

Reports Q4 revenue $2.91B, consensus $2.78B. “2024 marked a year of tremendous growth for Vertex and we anticipate 2025 will be another ...

Vertex Pharmaceuticals sees FY25 revenue $11.75B-$12.0B, consensus $11.85B Sees FY25 R&D, AIPR&D and SG&A expenses of $4.9B-$5.0B.

Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

Nevada has confirmed its first human case of bird flu in a farm worker who was exposed to infected dairy cattle, the Central ...

Amy Raskin, CIO at Chevy Chase Trust, joins CNBC's "Halftime Report" to detail her latest portfolio moves. Super Bowl 2025: ...

Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

The new Gemini 2.0 is now here for everyone to try. Google has announced that the latest version of their flagship AI model ...

Google had fallen far behind in the AI race but has gotten into the lead with Gemini 2.0. Google Gemini 2 is powerful, fast ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...